Medtech fundings for July 2016

Medtech fundings for July 2016 stand at $612 million, led by the $183 million IPO of Bioventus, followed by the $49 million Series C funding of VytronUS, the $32 million funding of Endotronix and the $30 million funding of Senseonics.

Below are the top fundings for the month thus far. Check back before month end to see updates.

Screen Shot 2016-07-29 at 8.38.14 AM

For a complete list of fundings in July 2016, see link.

June 2016 medtech fundings

Medtech fundings for June 2016 stand at $607 million, led by the $172.5 million post-IPO sale of Nevro’s convertible notes, the $75 million IPO (to happen in June) of OrthoPediatrics, and the $50 million funding of Clearside Biomedical.

Below are fundings for the month, thus far. Please revisit this post (and refresh your browser) for updates by month-end.

Screen Shot 2016-06-27 at 11.57.31 AM

For a complete list of fundings during June 2016.

Medtech midterm; Cardiovascular procedures; Wound shifts; Fundings

d5472bf8-1237-4ecc-a976-28a1b2fc7f3f.jpg

advanced medical technologies

A weekly(ish) newsletter to our blog subscribers.
From MedMarket Diligence, LLC
(Make note of this code: “Optinthirtyoff”)

From “Medtech is Dead. Long Live Medtech“, here is some of what we can expect in the next 5-10 years in medtech:

  • Type 1 diabetes gradually becomes less burdensome, with fewer complications, and improved quality of life for patients.
  • Type 2 diabetes continues to plague Western markets in particular, despite advances in diagnosis, treatment, and monitoring due to challenges in patient compliance.
  • Cancer five year survival rates will dramatically increase for many cancers. The number of hits on Google searches for “cure AND cancer” will reflect this.
  • Multifaceted approaches available for treatment of traumatic brain injury and spinal cord injury – encompassing exoskeletons to help retrain/rehabilitate and increase functional mobility, nerve grafting, cell/tissue therapy, and others.
  • Organ/device hybrids will proliferate and become viable alternatives to transplant, or bridge-to-transplant, for pulmonary assist, kidney, liver, heart, pancreas and other organ.
  • Stem cells have had dramatic success, and the science will have improved, but challenges remain, especially since the excitement around stem and other pluripotent cells has created a climate not far removed from the wild west – the potential of such open territory being up for grabs has drawn hordes of activity, not all in the best interests of patients or shareholders. But in this time frame, specific treatments will likely have become standards of care for some diseases, while the challenge and opportunity remain for many others.
From “Global Dynamics of Surgical and Interventional Cardiovascular Procedures, 2015-2022”.

Cardiovascular Surgical and Interventional Procedures

  • Coronary Artery Bypass Graft Surgery
  • Coronary Mechanical and Laser Atherectomy
  • Coronary Angioplasty and Stenting
  • Mechanical Thrombectomy
  • Ventricular Assist Device Placement
  • Total Artificial Heart
  • Donor Heart Transplantation
  • Lower Extremity Arterial Bypass Surgery
  • Percutaneous Transluminal Angioplasty (PTA) and Bare Metal Stenting
  • PTA and Drug-Eluting Stenting
  • PTA with Drug-Eluting Balloons
  • Mechanical and Laser Atherectomy
  • Catheter-Directed Thrombolysis and Thrombectomy
  • Surgical and Endovascular Thoracic Aortic Aneurysm Repair
  • Surgical and Endovascular Abdominal Aortic Aneurysm Repair
  • Vena Cava Filter Placement
  • Endovenous Ablation
  • Venous Revascularization
  • Carotid Endarterectomy
  • Carotid Artery Stenting
  • Cerebral Thrombectomy
  • Cerebral Aneurysm and Arteriovenous Malformation (AVM) repair
  • Congenital Heart Defect Repair
  • Heart Valve Repair and Replacement Surgery
  • Transcatheter Valve Repair and Replacement
  • Pacemaker Implantation
  • Implantable Cardioverter Defibrillator Placement
  • Cardiac Resynchronization Therapy Device Placement
  • Standard SVT Ablation
  • Surgical AFIb Ablation
  • Transcatheter AFib Ablation

See Report #C500, published August 2016.

From “Worldwide Wound Management, Forecast to 2024”, Report #S251, published December 2015

e40a6a3f-1b21-40de-98ba-3467c5698825.png
Source: Report #S251.

 

Selected Medtech Fundings, May 2016

7114c77d-d736-44de-89c4-cc3b76f8c6b8.png
Source: Compiled by MedMarket Diligence, LLC

Pending Reports from MedMarket Diligence:

  • Global Nanomedical Technologies, Markets and Opportunities, 2016-2021. Details.
  • Global Dynamics of Surgical and Interventional Cardiovascular Procedures, 2015-2022. Details.
  • Worldwide Markets for Medical and Surgical Sealants, Glues, and Hemostats, 2015-2022. Details.

Patrick Driscoll
(patrick)
MedMarket Diligence

New medical technologies at startups in December 2015

Listed below are the technologies under development at medical technology startups identified in December 2015 and added to the Medtech Startups Database.

  • 3D-printed, patient-specific implants
  • Therapeutic temperature management.
  • Vessel preparation angioplasty balloon.
  • Control system for minimally invasive surgical tools.
  • Surgical solutions focused on robotic and other technology.
  • Undisclosed products, but based on brain-gut pathway; principals with background in diabetes, endocrinology.
  • Robotically-assisted minimal access surgery.
  • Novel catheter device as a treatment for heart failure with preserved ejection fraction.

For a historical listing of medtech startups identified by month, see link.

Medtech Fundings for December 2015

Fundings in medical technology for December 2015 stand at $360.4 million, led by Spectranetics’ $110 million debt funding, followed by the $44 million launch funding of Kallyope, the $40 million funding of NxThera, and the $38.5 million funding of Axonics Modulation Technologies.

Below are the top fundings for the month, thus far. Please revisit this post (and refresh your browser) during December to see new medtech fundings.

For the complete list of fundings, see link.

For a month-by-month, historical list of fundings since 2009, see link.

Medtech fundings in June 2015

Medtech fundings in June reached a very respectable $777 million. Below are the top fundings in medtech for the month so far, led by the planned $135 million IPO of ConforMIS.

Company, fundingProduct/technology
ConforMIS, Inc., has filed to raised $135 million in an initial public offeringKnee implants and customized orthopedics
Calhoun Vision, Inc., has raised $69 million from $52 million in new financing and $17 million in debt conversion, according to the companyLight adjustable intraocular lens
Invuity, Inc., plans to raise $48 million (downgraded from an initial expectation of $73.6 million) in an initial public offering according to the companySurgical lighting
Corindus Vascular Robotics, Inc., plans to raise $41 million in a initial public offering according to press reportsRobotic percutaneous angioplasty

For the complete list of medtech fundings in June 2015, see link.

For a historical list of the individual fundings in medtech, by month, since 2009, see link.

Medtech Fundings in May 2015

Fundings for medical technologies in May 2015 came in at $757 million, led by the $96 million IPO of EndoChoice, Inc.

Below are the top fundings for May.

Company, fundingProduct/technology
EndoChoice, Inc., raised $96 million from a planned $115 million initial public offering according to the companyEndoscopy imaging and instruments
Glaukos Corp. has set terms for a $75 million (previously filed for $86 million) initial public offering according to a regulatory filingDevice-based treatment for glaucoma
Outset Medical, Inc., has raised $59.59 million of a planned $65.59 million round of funding according to a regulatory filingDialysis technology
Shockwave Medical, Inc., has raised $40 million in a round of funding according to the companyBalloon dilatation catheters integrated with lithotripsy for treatment of vascular and valvular lesions
Intact Vascular, Inc., has raised $38.9 million in a Series B round of funding according to the companyDevices for minimally invasive peripheral vascular procedures
Autonomic Technologies, Inc., has raised $38 million in a Series D round of funding according to the companyMicrostimulator for treatment of autonomic disorders, including severe headache
AirXpanders, Inc., has filed for a $36.5 million initial public offering according to the companyBreast tissue expander
AEGEA Medical, Inc., has raised $36 million in a Series C round of funding according to the companyConnective water vapor treatment for menorrhagia (abnormal uterine bleeding)
Ceterix Orthopedics, Inc., has secured $35 million in debt funding according to the companySurgical instruments and other products for treatment of soft tissue injuries
Moximed, Inc., has raised $33 million of a planned $37.64 million round of funding according to a regulatory filingExtra-capsular and extra-articular knee implant for treatment of osteoarthritis

For the complete list of medtech fundings in May 2015, see link.

For a historical list of the individual fundings in medtech, by month, since 2009, see link.

Medtech fundings in March 2015

Fundings for medical technologies in March 2015 totaled $542 million, led by the $57 million funding of EndoChoice, Inc.

Below are the top fundings for the month.

Company, fundingProduct/technology
EndoChoice, Inc., has raised $57 million in a round of funding, according to the companyEndoscopes and other instrumentation in gastroenterology
Apollo Endosurgery, Inc., has closed a $50 million secured term loan according to the companyMinimally invasive endoscopic surgical products for bariatric and gastrointestinal procedures
Semma Therapeutics has raised $44 million in a Series A round of funding according to the companyCell therapy for type I diabetes
Svelte Medical Systems, Inc., has raised $38.01 million of a planned $48.74 million round of funding according to a regulatory filingDrug eluting and other coronary stents
Auxogyn, Inc., has raised $34.32 million of a planned $40 million round of funding according to a regulatory filingDiagnostic and other technologies focused on women’s reproductive health
SteadyMed Therapeutics, Inc., has raised $39.95 million in its IPO according to press reportsPatch-pump drug delivery technology
Hansen Medical, Inc., has raised $35 million in a round of funding according to a regulatory filingIntravascular robotics

For the complete list of medtech fundings in March 2015, see link.

For a historical list of the individual fundings in medtech, by month, since 2009, see link.

Medtech fundings for October 2012 exceed $600 million, push up 2012 trend

Medical technology fundings for October 2012 totaled just over $600 million, comprised of many fundings, but with the biggest ones being:

  • $76.2 million for LifeTech Scientific Corp. (minimally invasive interventional devices for cardiovascular and peripheral vascular applications)
  • $60.2 million for Vital Therapies, Inc. (bioartificial liver device)
  • $45 million for EnteroMedics, Inc. (devices to treat obesity, metabolic disease and other GI disorders)
  • $45 million for Fibrocell Sciences, Inc. (autologous cell therapies for use in aesthetic dermatology)
  • $40 million for Alimera Sciences, Inc. (intravitreal implant for the treatment of chronic diabetic macular edema)
  • $35 million for Tornier NV (joint replacement and related orthopedic implants)
  • $31 million for InSightec Immage Guided Treatment Ltd (non-invasive MRI-guided ultrasound surgical devices)

The overall trend in medtech fundings has been a slow recovery from 2008. Indeed, recent press from venture capital associations and others have argued that fundings are at upwards of an eight year low.  The problem, however, with these reports is that they often look at medtech too narrowly (e.g., medical devices as opposed to medical devices, biomaterials and other products that are either complementary to or directly competitive with medical devices) or fail to account for fundings that come from both public and private investment, fundings from startup competitions, fundings from outside the U.S. Below is the actual trend, from 2009 though October 2012, based on individual financing we have tracked, month by month, since 2009 (you can see the individual fundings listed through June 2012 and the fundings separately for July, August, September and now October 2012).

Source: Compiled by MedMarket Diligence, LLC

Another way we have presented this data is to simply show the month-by-month financings with the seasonality (above) removed and a calculated trendline added. See below.

Source: Compiled by MedMarket Diligence, LLC 

 The data is hard and documented on these fundings, so the trendline above is not only reliable, but encouraging.